Insulin Delivery Pipeline Report Including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update
Summary
GlobalData's Medical Devices sector report, “Insulin Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update provides comprehensive information about the Insulin Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Insulin delivery devices are used to inject measured doses of insulin through the skin and into the fatty tissues below.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Insulin Delivery under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Insulin Delivery and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Insulin Delivery under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
About GlobalData
Introduction
Insulin Delivery Overview
Products under Development
Insulin Delivery - Pipeline Products by Stage of Development
Table Figure 1: Insulin Delivery - Pipeline Products by Stage of Development
Table Insulin Delivery - Pipeline Products by Stage of Development
Insulin Delivery - Pipeline Products by Segment
Table Figure 2: Insulin Delivery - Pipeline Products by Segment
Table Insulin Delivery - Pipeline Products by Segment
Insulin Delivery - Pipeline Products by Territory
Table Figure 3: Insulin Delivery - Pipeline Products by Territory
Table Insulin Delivery - Pipeline Products by Territory
Insulin Delivery - Pipeline Products by Regulatory Path
Table Omnipod 5 (Omnipod Horizon Hybrid Closed Loop System) - Efficacy and Safety of the Omnipod 5 System Compared to Pump Therapy in the Treatment of Type 1 Diabetes: A Randomized, Parallel-Group Clinical Trial
Table Omnipod 5 (Omnipod Horizon Hybrid Closed Loop System) - Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes
Table Omnipod 5 (Omnipod Horizon Hybrid Closed Loop System) - Randomized Controlled Trial to Demonstrate the Efficacy of the Omnipod(R) 5 System When Compared to Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT)
Table Omnipod 5 (Omnipod Horizon Hybrid Closed Loop System) - Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes
Iowa State University Company Overview
Iowa State University Pipeline Products & Ongoing Clinical Trials Overview
Table Iowa State University Pipeline Products & Ongoing Clinical Trials Overview
Table Feed Forward Insulin Delivery System - Product Status
Table Feed Forward Insulin Delivery System - Product Description
Kailian Medical Technology Co Ltd Company Overview
Kailian Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Kailian Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table InnoPen Electric Insulin Pen - Product Status
Table InnoPen Electric Insulin Pen - Product Description
Table InnoTouch Insulin Application Pump - Product Status
Table Afrezza Inhaler - INHALE-3: A 17-Week Randomized Trial and a 13-Week Extension, Evaluating the Efficacy and Safety of Inhaled Insulin (Afrezza) Combined with Insulin Degludec Versus Usual Care in Adults with Type 1 Diabetes
Medical International Technologies (Mit Canada) Inc Company Overview
Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview
Table Medical International Technologies (Mit Canada) Inc Pipeline Products & Ongoing Clinical Trials Overview
Table Minimed 780G - Adults - Advanced Hybrid Closed-Loop Treatment in Adults with Type 1 Diabetes Not Meeting Glycaemic Targets: A Randomized Controlled Trial - The Steno 780G Study
Table Minimed 780G - Adults - Automated Insulin Delivery in Type 1 Diabetes Complicated by Gastroparesis
Table Minimed 780G - Adults - Closed-Loop Insulin Delivery in Pregnant Women with Type 1 Diabetes
Table Minimed 780G - Adults - Closed-loop Insulin Delivery in Pregnant Women with Type 1 Diabetes: A Randomized Controlled Trial: The CRISTAL Study
Table Minimed 780G - Adults - Comparison With Observational Methods and Performance Assessment From Real-life Experience of Closed-Loop Insulin Delivery Systems
Table Minimed 780G - Adults - Effect of Advanced Automated Insulin Delivery on Glycaemia in Children and Young Adults with Type 1 Diabetes and High-risk Glycemic Control
Table Minimed 780G - Adults - Effect of an Artificial Pancreas System on Glycemic Control in Patients With Type 1 Diabetes
Table Minimed 780G - Adults - Effect of Automated Insulin Delivery with Advanced Closed-loop on Glucose Outcomes and Early-stage Diabetic Complications
Table Minimed 780G - Adults - Evaluation of the MiniMed 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp (Insulin Aspart Injection)
Table Minimed 780G - Adults - Feasibility Study for a Medtronic next Generation Hybrid Closed Loop System in Adults with Type 1 Diabetes
Table Minimed 780G - Adults - In-Home Study With MiniMed 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes
Table Minimed 780G - Adults - Open-label, Randomized, Controlled Clinical Trial to Evaluate the Efficacy of the Smart Insulin Pen Associated With a Continuous Glucose Monitoring System Compared to a Closed Loop System in Patients With Type 1 Diabetes (EBIACE-1)
Table Minimed 780G - Adults - Safety and Effectiveness Evaluation of the MiniMed 780G System Used in Combination With the DS5 CGM
Table Minimed 780G - Adults - Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects
Table Minimed 780G - Adults - Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adult and Pediatric Subjects Utilizing Lyumjev Insulin Lispro-aabc
Table Minimed 780G - Adults - The Impact of Daily CarboHydrate Intake on Glycemic Control in Children and Adolescents With Type 1 Diabetes Using an Advanced Hybrid Closed-loop System (Medtronic MiniMed 780G): a Multi-center Real-world Observational Study
Table Minimed 780G - Adults - Transition of Patients with T1D From Multiple Daily Injection (MDI) and Self-monitoring of Blood Glucose (SMBG) Directly to MiniMed 780G Advanced Hybrid Closed Loop (AHCL) System :Impact on Glucose Control and Quality of Life Measures
Table Tandem Mobi Insulin Pump With Interoperable Technology - Product Status
Table Tandem Mobi Insulin Pump With Interoperable Technology - Product Description
Table Tandem Mobi: Tubeless - Product Status
Table Tandem Mobi: Tubeless - Product Description
Table Tandem Patch - Product Status
Table Tandem Patch - Product Description
Table Tandem Diabetes Care Inc - Ongoing Clinical Trials Overview
Table CSII Catheter - A Pilot Study for the Systematic Evaluation of the Inflammatory Response to Commercially Available Insulin Infusion Catheters in Subcutaneous Adipose Tissue
Table SteadiSet Infusion Set - A Pivotal, Non-randomized, Prospective and Single Arm Study to Evaluate SteadiFlow Seven-day-wear Infusion Set Technology in Type I Diabetes Subjects
TempraMed Israel Ltd Company Overview
TempraMed Israel Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table Ypsomed Holding AG - Ongoing Clinical Trials Overview
Table mylife YpsoPump - An Open-label, Multi-center, Randomized, Two Arm Single Period Parallel Study to Assess the Efficacy, Safety and Utility of Hybrid Closed-loop Glucose Control Compared to Standard Insulin Therapy Combined with Continuous Glucose Monitoring in Young People (Greater Than or Equal to 16 Years) and Adults with Cystic Fibrosis Related Diabetes (Cl4p-cf Study)
Table mylife YpsoPump - Feasibility of Automated Insulin Delivery with an Interoperable Algorithm Using an Alternative Insulin Pump
Table mylife YpsoPump - First in Human Feasibility Study; Automated Insulin Delivery Utilizing the Dexcom Next Generation Algorithm in Adults with Type 1 Diabetes
Table Integrated Automated Insulin Delivery (AID) System - Randomized Open Label Clinical Trial Examining the Safety and Efficacy of the Android Artificial Pancreas System (AAPS) with Advanced Bolus-free Features in Adults with Type 1 Diabetes
Zealand Pharma AS Company Overview
Zealand Pharma AS Pipeline Products & Ongoing Clinical Trials Overview